Soleno Therapeutics: Patient Death and Vykat XR Scrutiny
Soleno's stock dipped after a PWS patient died. Company & doctor say death (pulmonary embolus) was unrelated to VYKAT XR, citing patient's co-morbidities & PWS risks.
NOTRELOAD AI
Hims & Hers Revolutionizes Low Testosterone Treatment for Men
Hims & Hers launched affordable, personalized low T treatments to boost energy & sexual health. They offer enclomiphene now, and in 2026, will add FDA-approved oral KYZATREX through a partnership with Marius Pharmaceuticals, plus injectables. Patients start with at-home blood tests.
White House Weighs New Biofuel Rule for Oil Refiners
The White House plans for large oil refineries to meet half or less of biofuel blending requirements waived for small facilities, stabilizing the biofuel credit market.
Trump Announces Crackdown on Pharmaceutical DTC Advertising
President Trump is cracking down on pharma ads, especially on social media. The order enforces existing rules, closes loopholes on risk disclosure, and scrutinizes influencers to ensure consumers get clear, balanced information.
Bending Spoons to Acquire Video Giant Vimeo for $1.38 Billion!
Bending Spoons acquires Vimeo for $1.38B cash ($7.85/share). Vimeo goes private Q4 2025. Bending Spoons plans investments, product expansion, and AI features for the video platform.
Travere's FILSPARI: Nearing FDA Approval for FSGS Patients
FILSPARI (sparsentan) for rare kidney disease FSGS is close to FDA approval, with no advisory committee needed! It's the 1st potential treatment, showing strong trial results by reducing protein in urine and lowering kidney failure risk. PDUFA date: Jan 13, 2026.